Correlation between disease activity and outcomes (damage accrual, mortality, QoL) | 257 |
Low disease activity and remission as surrogates of therapeutic success against outcomes | 40 |
Benefits and harms of treating serologically active but clinically quiescent disease | 2 |
Validated definitions of flares of disease activity against outcomes | 27 |
Is sustained remission or prevention of flares an achievable goal? | 95 |
Correlation between chronic, irreversible organ damage and mortality | 74 |
Correlation between chronic, irreversible organ damage and QoL | 49 |
Early vs late, and intensive vs less intensive control of disease activity | 48 |
‘Induction-maintenance’ vs ‘induction-only’ treatment strategy | 4 |
Long-term benefits and harms of glucocorticoids regimes in chronic maintenance treatment | 61 |
Benefits and harms of anticoagulation regimens in patients with antiphospholipid antibodies | 12 |
Benefits and harms of adjunct therapies | 50 |